News | July 20, 2021
Balaxi Pharmaceuticals Q1 revenue increases by 12%
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
The company plans to enter the EU markets in FY22
The Government of India has started importing the vital drug Remdesivir from other countries to ease out the shortage of Remdesivir in the country
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
Subscribe To Our Newsletter & Stay Updated
